Epinex's Scientific Advisory Board, Alan Carter Presents at ADA
June 14, 2017
Saturday June 10 2017, Epinex’s scientific advisory board member, Alan Carter presented at the American Diabetes Association’s (ADA) 77th scientific session. Alan Carter presented during the ADA symposium session "Dealing with the Rising Costs of Insulin-An Active Dialogue". His portion was titled "Understanding the Players in the Rising Costs of Insulin".
Alan Carter currently is a contracted Principal Investigator (PI) for NIH-NINDS Drug Manufacturing and Formulation and the NIH-NCATS Drug Substance Development and Manufacture programs.
He has over 20 years of experience directing multi-state business operations for a chain of community pharmacies, clinical pharmacy practice, and hospital pharmacy practice.
Dr. Carter has been responsible for multisite management of clinical trials for the evaluation and design of biologic metabolic markers and medical devices. He has provided disease management/formulary consulting for employers, health care plans, and biotech companies. Dr. Carter's expertise has been used by companies such as Argus Health Systems, Children's Mercy Family Health Partners, Johnson & Johnson Lifescan Division, LXN, Lockheed Martin Aerospace, and the US Army Research Institute of Environmental Medicine.
Alan Carter Presenting at the American Diabetes Association’s (ADA) 77th scientific session
Also in attendance, was Epinex CEO, Asad Zaidi
Epinex Scientific Advisory Board: Dr. David Horwitz (Left) and Alan Carter, PharmD (Right)